Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Quoted Policy Legislation

QUOTED. Jan. 23, 2018. Scott Whitaker.

  • News

Executive Summary

Check out what AdvaMed CEO Scott Whitaker had to say about Congress’ move to suspend the device tax after many fits and starts in 2017.

"Congress' action to once again suspend the medical device tax – just days before companies were set to start cutting checks to the IRS – means funds will not be diverted from investing in new jobs, new capital improvements, and new treatments and cures. We appreciate Congress' action." –Scott Whitaker, president and CEO, AdvaMed

> Find out more: US Senate Votes To End Shutdown, Clinches Two-Year Device-Tax Repeal

Click here for a free trial of Medtech Insight

Table

View full table

Related Content

Medtech Insight

Topics

Tags:
Quoted Policy Legislation
Latest Headlines

Shuren Says CDRH Is ‘Turning The Ship Around’ As Operations Return To Normal

EU: Good News For IVDs And For Future Transparency Of Medtech Compliance

Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease

Small Sterilization Companies Poised To Meet EtO Emissions Goals On Time

See All
UsernamePublicRestriction

Register

MT122070

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By